Cluster page — medicines optimisation
Prescribing cost optimisation
Cost as a quality measure
Why prescribing cost is a proxy for prescribing quality
Prescribing cost variation between PCNs in the same ICB rarely reflects population health difference — it reflects formulary adherence, prescribing habit, and the maturity of the local switch and deprescribing programme. Prescribing cost optimisation is therefore best understood not as a cost-saving exercise but as a quality proxy: the PCN with disciplined formulary alignment and structured deprescribing reliably has lower prescribing cost per weighted patient than the PCN without.
A mature PCN cost programme runs against ePACT2 and OpenPrescribing comparators, with quarterly outlier reviews driven by the Lead Pharmacist and delivered through clinical pharmacist-led patient-level switch consultations.
Cost workstreams
Where PCN savings actually come from
- Branded-to-generic switching where bioequivalent (the largest category)
- Biosimilar transitions in shared-care prescribing areas
- Formulary alignment on first-line statin, ACE-i, antiplatelet, PPI, inhaler
- Waste reduction through repeat prescribing redesign and synchronisation
- Deprescribing in over-75s and care home cohort (cost as secondary benefit)
- Switch from blister-pack to original-pack dispensing where appropriate
- Stoma, wound care and emollient prescribing review against formulary
Savings benchmarks
What good cost programmes deliver
Frequently asked questions
Cost & savings — FAQs
What is ePACT2?+
The NHS Business Services Authority's prescribing analytics platform — the authoritative source for primary care dispensing data. PCNs and ICBs use it to benchmark prescribing cost, identify outliers and track switch programme outcomes.
What is OpenPrescribing.net?+
An open-data prescribing benchmarking platform developed by the Bennett Institute (Oxford), used widely by ICB medicines optimisation teams and PCN Lead Pharmacists for comparator dashboards.
Where do PCN prescribing savings come from?+
Branded-to-generic switching where bioequivalent, biosimilar transitions in shared-care areas, formulary alignment on first-line therapy (e.g. statins, ACE-i, antiplatelets), waste reduction via repeat prescribing redesign, and deprescribing.
Do prescribing savings compromise care quality?+
Done properly, no. Savings come from removing waste (over-ordering, inappropriate continuation), aligning to evidence-based first-line therapy, and using equivalent cheaper formulations. Switches are individualised and patient-consented; patients are not switched on cost grounds where clinically inappropriate.
Talk to our Service Development team
30-minute discovery call. We'll show you how BCS maps to your PCN's specific priorities.